DRD2 Gene

📖 Wiki Page

gene1116 wordssynced 2026-04-02

DRD2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DRD2 — Dopamine Receptor D2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DRD2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Dopamine Receptor D2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q23.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/1819" target="_blank">1819</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149295" target="_blank">ENSG00000149295</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P14416" target="_blank">P14416</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Schizophrenia](/diseases/schizophrenia), [Parkinsonism](/diseases/parkinsonism)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Striatum, Substantia nigra, Pituitary, [Cortex](/brain-regions/cortex)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a h

...

DRD2 Gene

DRD2 — Dopamine Receptor D2

Pathway Diagram

Mermaid diagram (expand to render)

Introduction

Drd2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

DRD2 (Dopamine Receptor D2) encodes the D2 dopamine receptor, a G protein-coupled receptor that inhibits adenylyl cyclase and reduces intracellular cAMP. It functions as both a presynaptic autoreceptor and postsynaptic receptor, critical for motor control, reward, and prolactin regulation[@beaulieu2011].

Function

Signaling

Gi/o coupling: Inhibits adenylyl cyclase
Reduced cAMP: Decreases PKA activity
Beta-arrestin pathways: G protein-independent signaling
GIRK channel activation: Hyperpolarization through potassium channels
PI3K/Akt pathway: Anti-apoptotic signaling

Brain Functions

Motor inhibition: Indirect pathway in basal ganglia[@drd2_striatum]
Reward: Modulates dopaminergic tone
Presynaptic autoreceptor: Regulates dopamine release[@drd2_autoreceptor]
Motor learning: Procedural memory formation
Endocrine control: Prolactin inhibition[@drd2_prolactin]

Pre- vs Postsynaptic Localization

Presynaptic D2 receptors (autoreceptors):

Located on dopamine neuron terminals
Detect ambient dopamine levels
Inhibit dopamine release (negative feedback)
Regulate firing rate through somatodendritic signaling
Lower affinity for dopamine than postsynaptic receptors

Postsynaptic D2 receptors:

Located on indirect pathway striatal neurons
Also on cortex, hippocampus, amygdala
Mediate motor inhibition and reward modulation
Different isoforms: D2S (short) and D2L (long)

Disease Associations

Parkinson's Disease

Primary therapeutic target for motor symptoms
D2 agonists (ropinirole, pramipexole, rotigotine)
Levodopa works through D2 receptors

Schizophrenia

D2 receptor blockade by antipsychotics
D2 hypersensitivity theory
Most antipsychotics are D2 antagonists

Prolactinomas

D2 receptors inhibit prolactin secretion
D2 agonists treat hyperprolactinemia

Alzheimer's Disease

D2 receptor expression changes in AD
Interactions with cholinergic system
Cognitive effects of D2 modulation
Potential for neuropsychiatric symptoms

Huntington's Disease

Early loss of D2 receptors
Contributes to motor dysfunction
D2 agonist trials in HD

Neurodegeneration Mechanisms

Dopamine Signaling Dysregulation

Loss of D2 autoreceptor function leads to excessive dopamine release
Excitotoxic vulnerability from dysregulated neurotransmission
Oxidative stress from dopamine metabolism

Receptor Trafficking

D2 receptor internalization in PD
Altered desensitization patterns
Impaired receptor recycling

Neuroinflammation

D2 receptors on microglia
Anti-inflammatory effects of D2 activation
Therapeutic implications for PD

Protein Isoforms

D2S (Short) isoform

Predominantly presynaptic
Functions as autoreceptor
Alternative splicing creates isoforms

D2L (Long) isoform

Predominantly postsynaptic
Mediates motor inhibition
Expressed in striatum

Therapeutic Targeting

Parkinson's Disease

D2 receptors are the primary therapeutic target for PD motor symptoms. Several drug classes target D2 receptors:

D2 Agonists: Ropinirole, Pramipexole, Rotigotine, Apomorphine
Dopamine Replacement: Levodopa (converted to dopamine, activates D2)
COMT Inhibitors: Entacapone, Opicapone (prolong levodopa effect)

Schizophrenia

Most antipsychotics work by blocking D2 receptors:

First-generation: Haloperidol, Chlorpromazine
Second-generation: Risperidone, Olanzapine, Quetiapine, Aripiprazole (partial agonist)

Restless Legs Syndrome (RLS)

D2 agonists are first-line treatment for RLS

Molecular Mechanism

G Protein Signaling

The D2 receptor couples to Gi/o proteins, leading to:

Inhibition of adenylyl cyclase

Reduced cAMP production

Decreased PKA activity

Reduced phosphorylation of DARPP-32

Activation of GIRK channels → hyperpolarization

Beta-Arrestin Pathway

D2 receptors can signal through beta-arrestin independently of G proteins, which may contribute to:

Receptor desensitization
Beta-arrestin mediated MAPK activation
Distinct behavioral effects

Receptor Oligomerization

D2 can form homomers
D1-D2 heteromers have unique signaling
Receptor-receptor interactions in disease

Basal Ganglia Circuitry

Indirect Pathway

The "braking" pathway involves D2 receptors:

Cortex → striatum (D2 neurons)

D2 neurons → external globus pallidus (GPe)

GPe inhibits subthalamic nucleus (STN)

STN excites substantia nigra pars reticulata (SNr)

SNr inhibits thalamus → reduced movement

D2 in Network Context

D2 neurons receive input from associative/cognitive cortices
D2 has shorter dendritic spines
D2 signaling reduces signal-to-noise ratio
Loss of D2 neurons contributes to hypokinesia

Genetic Variations

Polymorphisms

Taq1A A1 allele: Associated with reduced D2 receptor density
C957T: Affects receptor binding affinity
-141C Ins/Del: Alters promoter activity
These variants may influence:
Response to antipsychotics
Risk of addiction
[Parkinson's disease](/diseases/parkinsons-disease-disease) progression

Clinical Genetics

DRD2 variants predict antipsychotic response
Side effect profiles associated with specific alleles
Pharmacogenomic testing for clozapine, risperidone

Animal Models

Knockout Studies

Drd2 knockout mice show hyperactivity
Impaired presynaptic regulation
Reward deficits

Transgenic Models

D2 overexpression: reduced locomotion
Cre driver lines for cell-specific manipulation

Clinical Considerations

Therapeutic Implications

D2 agonists for PD motor symptoms
Antipsychotic-induced hyperprolactinemia
D2 partial agonists for schizophrenia

Adverse Effects

Dyskinesia with long-term agonist use
Impulse control disorders
Sleep attacks

References

Research Directions

D2-Selective Agents

Developing biased agonists favoring G protein over beta-arrestin pathways
Allosteric modulators for greater selectivity
Bitopic ligands combining orthosteric and allosteric binding

Gene Therapy

AAV-mediated D2 overexpression in preclinical models
CRISPR approaches to modulate DRD2 expression

External Links

[NCBI Gene: DRD2](https://www.ncbi.nlm.nih.gov/gene/1819)
[UniProt: DRD2](https://www.uniprot.org/uniprot/P14416)

Background

The study of Drd2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Beaulieu JM, Gainetdinov RR, The physiology, signaling, and pharmacology of dopamine receptors (2011)](https://pubmed.ncbi.nlm.nih.gov/21303898/)

[Missale C, Nash SR, Robinson SW, Jaber M, Caron MG, Dopamine receptors: from structure to function (1998)](https://pubmed.ncbi.nlm.nih.gov/9457173/)

[Levant B, The D2 dopamine receptor: neurobiology and potential clinical relevance (1997)](https://pubmed.ncbi.nlm.nih.gov/9228665/)

[Strange PG, Dopamine receptors in the basal ganglia: relevance to Parkinson's disease (1999)](https://pubmed.ncbi.nlm.nih.gov/10495032/)

[Seeman P, Van Tol HH, Dopamine receptor pharmacology (1994)](https://pubmed.ncbi.nlm.nih.gov/7946700/)

[Gerfen CR, D1 and D2 dopamine receptor-regulated gene expression in the striatum (1995)](https://pubmed.ncbi.nlm.nih.gov/7530793/)

[Carlsson A, A paradigm shift in brain research (2001)](https://pubmed.ncbi.nlm.nih.gov/11691980/)

[Fuxe K, Borroto-Escuela DO, Volume transmission and receptor-receptor interactions in striatal dopamine neurons (2014)](https://pubmed.ncbi.nlm.nih.gov/25426028/)

[D2 dopamine receptor regulation of striatal function (PMID:19773757)](https://pubmed.ncbi.nlm.nih.gov/19773757/)

[Presynaptic D2 dopamine receptors: synthesis and release (PMID:16818524)](https://pubmed.ncbi.nlm.nih.gov/16818524/)

[D2 autoreceptor function in dopamine neurons (PMID:22120469)](https://pubmed.ncbi.nlm.nih.gov/22120469/)

[D2 dopamine receptor and antipsychotic drug action (PMID:29249657)](https://pubmed.ncbi.nlm.nih.gov/29249657/)

[D2 dopamine receptor regulation of prolactin secretion (PMID:20158839)](https://pubmed.ncbi.nlm.nih.gov/20158839/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DRD2/SNCA

Pathway Diagram

The following diagram shows the key molecular relationships involving DRD2 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

DRD2 Gene

DRD2 Gene

DRD2 Gene

DRD2 — Dopamine Receptor D2

Pathway Diagram

Introduction

Overview

Function

Signaling

Brain Functions

Pre- vs Postsynaptic Localization

Disease Associations

Parkinson's Disease

Schizophrenia

Prolactinomas

Alzheimer's Disease

Huntington's Disease

Neurodegeneration Mechanisms

Dopamine Signaling Dysregulation

Receptor Trafficking

Neuroinflammation

Protein Isoforms

D2S (Short) isoform

D2L (Long) isoform

Therapeutic Targeting

Parkinson's Disease

Schizophrenia

Restless Legs Syndrome (RLS)

Molecular Mechanism

G Protein Signaling

Beta-Arrestin Pathway

Receptor Oligomerization

Basal Ganglia Circuitry

Indirect Pathway

D2 in Network Context

Genetic Variations

Polymorphisms

Clinical Genetics

Animal Models

Knockout Studies

Transgenic Models

Clinical Considerations

Therapeutic Implications

Adverse Effects

References

Research Directions

D2-Selective Agents

Gene Therapy

See Also

External Links

Background

References

Related Hypotheses

Pathway Diagram